338 related articles for article (PubMed ID: 15540755)
41. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
[TBL] [Abstract][Full Text] [Related]
42. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
[TBL] [Abstract][Full Text] [Related]
43. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease.
Zesiewicz TA; Evatt M; Vaughan CP; Jahan I; Singer C; Ordorica R; Salemi JL; Shaw JD; Sullivan KL;
Parkinsonism Relat Disord; 2015 May; 21(5):514-20. PubMed ID: 25814050
[TBL] [Abstract][Full Text] [Related]
44. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.
Kelleher C; Cardozo L; Kobashi K; Lucente V
Int Urogynecol J Pelvic Floor Dysfunct; 2006 Jun; 17(4):382-8. PubMed ID: 16283422
[TBL] [Abstract][Full Text] [Related]
45. Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?
Cardozo L; Herschorn S; Snijder R; Siddiqui E; Chapple CR
Int Urogynecol J; 2017 Mar; 28(3):477-488. PubMed ID: 27605255
[TBL] [Abstract][Full Text] [Related]
46. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
Staskin DR; Te AE
BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
[TBL] [Abstract][Full Text] [Related]
47. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
48. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity.
Landis JR; Kaplan S; Swift S; Versi E
J Urol; 2004 Feb; 171(2 Pt 1):752-6. PubMed ID: 14713803
[TBL] [Abstract][Full Text] [Related]
50. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
51. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
Brubaker L; FitzGerald MP
Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jul; 18(7):737-41. PubMed ID: 17131169
[TBL] [Abstract][Full Text] [Related]
52. Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder.
Chancellor M; Versi E; Dvergsten C; Toler S
J Urol; 2015 Nov; 194(5):1329-35. PubMed ID: 26073872
[TBL] [Abstract][Full Text] [Related]
53. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.
Cardozo L; Castro-Diaz D; Gittelman M; Ridder A; Huang M
Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):512-9. PubMed ID: 16625311
[TBL] [Abstract][Full Text] [Related]
54. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
55. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
Haab F; Cardozo L; Chapple C; Ridder AM;
Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
[TBL] [Abstract][Full Text] [Related]
56. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
57. A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy.
Bianco FJ; Albala DM; Belkoff LH; Miles BJ; Peabody JO; He W; Bradt JS; Haas GP; Ahlering TE
J Urol; 2015 Apr; 193(4):1305-10. PubMed ID: 25281778
[TBL] [Abstract][Full Text] [Related]
58. Solifenacin succinate for the treatment of symptoms of overactive bladder.
Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
[TBL] [Abstract][Full Text] [Related]
59. Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder.
Newgreen D; Bosman B; Hollestein-Havelaar A; Dahler E; Besuyen R; Snijder R; Sawyer W; Rittig S; Bolduc S
J Urol; 2017 Oct; 198(4):928-936. PubMed ID: 28506854
[TBL] [Abstract][Full Text] [Related]
60. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.
Metello J; Nogueira B; Torgal M; Colaço J; Vieira A; Gonçalves V; Retto H
Int Urogynecol J Pelvic Floor Dysfunct; 2007 Sep; 18(9):1021-5. PubMed ID: 17211528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
